360° SearchNetwork Hot Spots Trends Time Series

xenograft

Type: Keyphrase

Name: xenograft

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Global Metabolite Profiling of Human Colorectal Cancer Xenografts in Mice Using HPLC–MS/MS

Reversed-phase gradient LC–MS was used to perform untargeted metabonomic analysis on extracts of human colorectal cancer (CRC) cell lines (COLO 205, HT-29, HCT 116 and SW620) subcutaneously implanted into age-matched athymic nude male mice to study small ... [Published Journal of Proteome Research - May 22 2013]

Entities: xenograft, Metabolite, Tumor, Colorectal Cancer

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Variant G6PD levels promote tumor cell proliferation or apoptosis via the STAT3/5 pathway in the human melanoma xenograft mouse model

Glucose-6-phosphate dehydrogenase (G6PD), elevated in tumor cells, catalyzes the first reaction in the pentose-phosphate pathway. The regulation mechanism of G6PD and pathological change in human melanoma growth remains unknown.HEM (human epidermal melanocyte) ... [Published BMC - May 22 2013]

Entities: Apoptosis, Skin Cancer, xenograft, Cell Proliferation, Tumor

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Egenix, Inc. Announces New Director

--Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention ... [Published Sacramento Bee - May 21 2013]

Entities: Cancer, Apoptosis, Tumor, Gene Product

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Reversal of Multidrug Resistance by Mitochondrial Targeted Self-Assembled Nanocarrier Based on Stearylamine

Multidrug resistance (MDR) remains one of the major challenges for successful chemotherapy. Herein, we tried to develope a mitochondria targeted teniposide loaded self-assembled nanocarrier based on stearylamine (SA-TSN) to reverse MDR of breast cancer. ... [Published Molecular Pharmaceutics - May 17 2013]

Entities: teniposide, multidrug resistance, mitochondria

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Hypoxic Tumor Kinase Signaling Mediated by STAT5A in Development of Castration-Resistant Prostate Cancer

by Kathrine Røe, Åse Bratland, Ljiljana Vlatkovic, Harald Bull Ragnum, Marie Grøn Saelen, Dag Rune Olsen, Laure Marignol, Anne Hansen ReeIn this study, we hypothesized that androgen-deprivation therapy (ADT) in prostate cancer, although initially efficient, ... [Published Elites TV - May 10 2013]

Entities: Kinase, Tumor, hypoxic, Castrate-Resistant, Hypoxia

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Investigators at University of Texas Target Lung Cancer

(NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Lung Cancer have been published. According to news originating from Houston, Texas, by NewsRx correspondents, research stated, "NSC-743380 is a novel STAT3 inhibitor ... [Published NewsRX - May 10 2013]

Entities: Lung Cancer, University of Texas, Cell Lines

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Gossypin Blocks Melanoma Growth in Culture and Xenograft Models

Gossypin, a glucoside occurring in cotton and Hibiscus flowers, has been shown to be a potent drug for the treatment for melanoma, which causes the majority of deaths from skin cancer.Mutation in the BRAF gene (BRAF-V600E) is present in nearly 70% of ... [Published Biotech Daily - May 08 2013]

Entities: Skin Cancer, Kinase, xenograft

First reported May 07 2013 - Updated May 08 2013 - 2 reports

PRECOS Showcased Preclinical Oncology Service Portfolio at the AACR Annual Meeting 2013

In addition to unveiling its new PUMA platform, PRECOS ran four poster presentations at the show covering a range of preclinical research studies. This year’s meeting carried the theme of “Personalized Cancer Care Through Discovery Science” and brought ... [Published Web Newswire - May 08 2013]

Entities: In Vivo, Oncology, xenograft, non-small cell lung cancer

First reported May 04 2013 - Updated May 04 2013 - 2 reports

Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in ...

Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive and associated with poor prognosis. Basic research to develop new treatment regimens is critically needed.Methods: The effects of imatinib mesylate on MPNSTs were examined in six ... [Published 7thSpace - May 04 2013]

Entities: imatinib mesylate, In Vitro, Cell Lines

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Origin of the vasculature supporting growth of primary patient tumor xenografts

Studies of primary patient tumor xenografts grown in immunodeficient mice have shown that these tumors histologically and genetically closely resemble the original tumors. These patient xenograft models are becoming widely used for therapeutic efficacy ... [Published 7thSpace - May 03 2013]

Entities: Tumor, xenograft, Vessel, Stroma, perfusion

First reported May 01 2013 - Updated May 02 2013 - 2 reports

PRECOS Showcased Preclinical Oncology Service Portfolio at the AACR Annual Meeting 2013

Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology, unveiled its new PUMA platform for preclinical oncology research at the AACR (American Association of ... [Published Pharma-Mag - May 02 2013]

Entities: Oncology, In Vivo, xenograft, non-small cell lung cancer

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft ...

Malignant pleural effusion (MPE) is associated with advanced stages of lung cancer and is mainly dependent on invasion of the pleura and expression of vascular endothelial growth factor (VEGF) by cancer cells. As MPE indicates an incurable disease with ... [Published 7thSpace - May 01 2013]

Entities: oncolytic, xenograft, malignant, Vaccinia

Quotes

According to the news editors, the research concluded: "These results suggest that MSC-TRAIL is sufficiently effective in inhibiting MFH-ino metastasis and the application using MSC-TRAIL could be extended to other sarcomas and recurrent metastatic cancers for cell-mediated cancer therapy."

Recent Research from CHA Stem Cell Institute Highlight Findi. . . [Published Equities.com - May 22 2013]

...“It has been very difficult for us to sell these intermittent dosing trials because there is this default view that "of course you have to give it every single day." But, of course, it is possible that intermittent or pulse dosing may allow for dose escalation and thus more potent target inhibition...

Keeping Tumors Off Guard: Intermittent Dosing May Prolong Vemurafenib Sensitivity in Melanoma [Published Oncology Times - May 18 2013]

This Media Release contains forward looking statements. The words "believe-, "expect-, "anticipate-, "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements in relation to actual results, unless required by law."

Genmab A/S: Daratumumab Data to be Presented at ASCO Annual Meeting [Published FinanzNachrichten.de - May 15 2013]

...of VS-6063 plus paclitaxel for ovarian cancer is open and enrolling patients at all sites," said Robert Forrester, President and COO of Verastem. "In addition, we met with the regulatory agencies in the US and UK and are on track to initiate midyear the potentially pivotal trial of VS-6063 in mesothelioma."

Verastem Posts First Quarter 2013 Financial and Corporate Results [Published Individual.com - May 14 2013]

More Content

sort by: Date \| Relevance
Cenix, Debiopharm Launch Biomarker Collaboration [Published Genetic Engineering News - 1 hour ago]
Mesenchymal Stem Cells as Vectors for Lung Canc... [Published Sexual Development - 5 hours ago]
Reversal of Multidrug Resistance by Mitochondri... [Published Bionity.com - 19 hours ago]
Ponatinib Shows Strong Activity in Medullary Th... [Published Oncology Times - 20 hours ago]
Global Metabolite Profiling of Human Colorectal... [Published Journal of Proteome Research - May 22 2013]
Regenerative Medicine Markets [Published Zecco - May 22 2013]
Recent Research from CHA Stem Cell Institute Hi... [Published Equities.com - May 22 2013]
Variant G6PD levels promote tumor cell prolifer... [Published BMC - May 22 2013]
Egenix, Inc. Announces New Director [Published Sacramento Bee - May 21 2013]
Tissue engineering rib with the incorporation o... [Published 7thSpace - May 20 2013]
Keeping Tumors Off Guard: Intermittent Dosing M... [Published Oncology Times - May 18 2013]
ERK Inhibitor May Overcome Resistance to MEK an... [Published Oncology Times - May 18 2013]
Reversal of Multidrug Resistance by Mitochondri... [Published Molecular Pharmaceutics - May 17 2013]
Novel Insights into the Synergistic Interaction... [Published Elites TV - May 17 2013]
Cancer Metabolism as a Therapeutic Target: Meta... [Published Cancernetwork.com - May 16 2013]
Daratumumab Data to be Presented at ASCO Annual... [Published EuroInvestor - May 15 2013]
Daratumumab Data to be Presented at ASCO Annual... [Published NASDAQ OMX - May 15 2013]
Genmab A/S: Daratumumab Data to be Presented at... [Published FinanzNachrichten.de - May 15 2013]
Breakpoint Analysis of Transcriptional and Geno... [Published PLoS Biology - May 15 2013]
Anti-cancer effects of newly developed chemothe... [Published BMC - May 14 2013]
Human and mouse brain-derived endothelial cells... [Published 7thSpace - May 14 2013]
Verastem Posts First Quarter 2013 Financial and... [Published Individual.com - May 14 2013]
Soyfood Consumption in Breast Cancer Survivors:... [Published Cancernetwork.com - May 14 2013]
A pair of model-building aficionados [Published Drug Discovery News - May 13 2013]
Organosulfur Garlic Compounds Induce Neovasculo... [Published Journal of Agricultural and Food Chemistry - May 13 2013]
The expression and significance of insulin-like... [Published 7thSpace - May 12 2013]
LifeCell Corporation - Medical Equipment - Deal... [Published TransWorldNews - May 12 2013]
U.S. Patents Awarded to Inventors in New Jersey... [Published Equities.com - May 11 2013]
Cancer Biology: University of Alabama Reports F... [Published NewsRX - May 11 2013]
Hypoxic Tumor Kinase Signaling Mediated by STAT... [Published Elites TV - May 10 2013]

Blogs

sort by: Date \| Relevance
PRECOS Launched Portfolio of Techniques & Model... [Published Pharma-Mag - May 02 2013] Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology, launched P RECOS U nique M odels of A cquired resistance ( PUMA ) at the AACR annual meeting (Washington ...
PRECOS Showcased Preclinical Oncology Service P... [Published Pharma-Mag - May 02 2013] Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology, unveiled its new PUMA platform for preclinical oncology research at the AACR (American Association of ...
Asia shifting toward stratified medicine [Published RDD Blog - Mar 14 2013] Asia is the world’s growth engine, and is building its reputation as a hub for current and future healthcare R&D activities. There is an unprecedented growth in global health care R&D activities in the region with numerous multinational pharmaceutical ...
Stroke – Stem Cells Can Reduce Brain Damage [Published Brain Blogger - Feb 14 2013] Rescuing a patient from a stroke and restoring cognitive functions are two significant medical challenges today. Blockage of a brain artery, usually by a clot or atherosclerotic plaque, results in reduction in oxygen supply to brain cells. If the supply ...
More on Metformin and Cancer (and Alzheimer's) [Published In the Pipeline - Jan 17 2013] Metformin : what a weird compound it is. Very small, very polar, the sort of thing you'd probably cross off your list of screening hits. But it's been taken by untold millions of diabetics (and made untold billions of dollars in the process), because ...

Press Releases

sort by: Date \| Relevance
Taconic and Yecuris Corporation Announce Strate... [Published Marketwire - Breaking News Releases - Feb 22 2013]